USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer

doi:10.21203/rs.3.rs-4681501/v1

Download PDF

Article

USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer

https://doi.org/10.21203/rs.3.rs-4681501/v1

This work is licensed under a CC BY 4.0 License

You are reading this latest preprint version

Metastasis is a major challenge for colorectal cancer (CRC) treatment. Here, we uncovered CENPF may be involved in CRC metastasis through bioinformatics mining and small interfering RNA (siRNA) targeted functional screening. We observed CENPF expression was preferentially increased in CRC tissues compared to adjacent normal tissues. More importantly, multicenter cohort study identified upregulated CENPF expression was significantly correlated with poor survival in CRC. Knockdown of CENPF inhibited CRC cell invasion and metastasis in vitro and in vivo. Intriguingly, we found CENPF undergoes degradation in CRC via the ubiquitination-proteasome pathway. Mechanistically, we observed that USP4 interacted with and stabilized CENPF via deubiquitination. Furthermore, USP4-mediated CENPF upregulation was critical regulators of metastasis of CRC. Examination of clinical samples confirmed that USP4 expression positively correlates with CENPF protein expression, but not mRNA transcript levels. Taken together, this study describes a novel USP4-CENPF signaling axis which is crucial for CRC metastasis, potentially serving as a therapeutic target and a promising prognostic biomarker for CRC.

Biological sciences/Cancer/Gastrointestinal cancer/Colorectal cancer

Health sciences/Biomarkers/Prognostic markers

USP4

CENPF

biomarker

deubiquitination

colorectal cancer

Colorectal cancer (CRC) is the second most common malignancy worldwide and ranks as the third leading cause of cancer-related deaths [1]. Despite the progress in treatment modalities, CRC recurrence remains a significant concern due to various factors such as tumor heterogeneity, microenvironmental influences, and acquired drug resistance. The recurrence of CRC often signifies a more aggressive disease phenotype, posing a considerable threat to patient survival. A thorough understanding of the molecular processes underlying CRC metastasis has the potential to reveal a plethora of new novel biomarkers and therapeutic targets.

The major type of genomic instability was chromosomal instability (CIN), which was observed in both pre-cancerous lesions and malignant growth [2]. CIN was characterized by frequent chromosomal abnormalities, including whole chromosome or large segmental gains/losses (non-diploidy), structural rearrangements, and focal aberrations (e.g., amplifications and deletions), resulting in tumor heterogeneity and other malignant features. The centromeres and their associated kinetochores were necessary for proper spindle attachment, chromosome alignment, mitotic checkpoint activation, and separation of sister chromatids during mitosis, which were considered major causes of CIN when abnormally expressed. Centromere proteins (CENPs) family participates in centromere formation and organization during mitosis. Centromere protein F (CENPF), one of the CENPs, is the largest member of the centromere protein family (approximately 350 kDa in molecular weight) and plays critical roles in protein complexes, participating in microtubule functions such as attachment and dynamics, centromere assembly, and mitotic checkpoints [3]. Recently, CENPF has been confirmed to potentially induce CIN in primary breast cancer and participate in the progression of various malignant tumors, making it a key factor in tumor progression and a promising indicator for prognosis [4–7]. However, the biological roles and prognostic value of CENPF in CRC remained unknown.

Ubiquitination, a vital posttranslational modification, orchestrates numerous cellular processes, such as cell-cycle advancement, transcriptional modulation, and signal transduction [8–10]. This process involves the attachment of ubiquitin molecules to target proteins, marking them for various fates within the cell. However, alongside ubiquitination, the reversal process known as deubiquitination, managed by deubiquitinating enzymes (DUBs), has emerged as a pivotal regulatory mechanism governing protein turnover [11, 12]. Deubiquitination, in essence, acts as a molecular undo button, removing ubiquitin molecules from target proteins and thereby influencing their stability, activity, and localization within the cell. In recent years, targeting DUBs to regulate ubiquitination modification of substrate proteins has become a hot research direction, and targeting DUBs is emerging as a promising agent for anticancer therapy [13, 14].

In this research, we employed bioinformatics approaches and conducted siRNA functional screening to identify CENPF as a pivotal gene involved in CRC metastasis. We utilized both in vitro and in vivo CRC cell models to investigate the functional role of CENPF. Additionally, we also evaluated the prognostic relevance of CENPF in CRC by analyzing data from multiple patient cohorts across three different medical centers. Furthermore, our study revealed that CENPF serves as a novel substrate for the Ub-specific protease (USP) family member USP4, a deubiquitinating enzyme closely associated with numerous oncogenic proteins [15–22]. Notably, the interaction between CENPF and USP4 is intricately linked to CRC metastasis. Collectively, these results supported a functional role of USP4-CENPF axis in CRC metastasis, potentially serving as a therapeutic target and a promising prognostic biomarker for CRC.

Identification of CENPF as a Potential Participant in CRC Progression

Autophagy is considered a self-degradative and conservative process[23], playing a crucial role in controlling the quality of cellular components and maintaining cellular homeostasis. Recently, it has been found that autophagy not only supports tumor growth in harsh environments but also plays a critical role in tumor metastasis [24–31]. To discover novel hub genes involved in CRC metastasis, we explored expression genes significantly correlated with the autophagy gene set using correlation analysis. Initially, we obtained the raw data from GSE14333, GSE41258, and TCGA gene sets, extracted the expression profile of autophagy genes and the remaining protein-coding genes, and performed correlation analysis on both sets. The potential autophagy-related gene sets (correlation > 0.3 and p < 0.001) were obtained for GSE14333, GSE41258, and TCGA gene sets, and their intersection was taken as the initial candidate set of 797 autophagy-related genes (Fig. 1A). We then compared those candidates with a group of genes that were highly expressed (logFC > 1 and fdr < 0.0001) in GSE41258 and GSE49355 datasets, resulting in 54 potential important CRC-related genes (Fig. 1B). We further narrowed down the candidate genes based on single-cell databases, literature searches to exclude stromal or immune cell localization, and previous studies on genes in CRC, focusing on 24 candidate genes that may play a role in CRC. We obtained two small interfering RNAs (siRNAs) targeting each of the 24 genes and a control siRNA (siCtrl), then transfected into HCT116 CRC cells separately, and evaluated the impact on the migration ability of HCT116 cells using migration assays. It was found that knocking down CENPF most significantly inhibited the migration of HCT116 cells (Fig. 1C), implying a possible tumor-promoting role in CRC metastasis. Thus, CENPF was selected as our major research object.

Also, we analyzed published CRC mRNA microarray datasets from GSE8671, GSE22598 and TCGA. In TCGA, we observed that the expression of CENPF mRNA is significantly elevated in colorectal cancer and rectal cancer, similar to many other broad-spectrum tumors, compared to adjacent normal tissues (Supplemental Fig. 1A). This finding is further validated by two additional datasets, GSE8671 and GSE22598, confirming the upregulation of CENPF expression in CRC (Supplemental Fig. 1, B and C). Additionally, we have collected an independent cohort of tissues microarrays (TMAs) composed of colorectal cancer and adjacent normal tissues (Cohort I). We examine the expression of CENPF protein using immunohistochemistry staining. We observed CENPF protein was mainly distributed in both cytoplasm and nucleus of colorectal epithelial cell as representative immunostaining presented (Fig. 1D), in which the expression pattern of CENPF protein mirrors that of mRNA expression (Fig. 1E).

To assess the potential prognostic significance of dysregulated CENPF expression in CRC, we then conducted time-to-event analyses using 3 cohorts with follow-up records. In GSE14333, it was found that higher CENPF expression in tumors was significantly associated with decreased DFS (HR 2.821, 95% CI 1.792 to 4.441, Log-rank p < 0.0001) (Fig. 1F). In Cohort I, high CENPF protein expression was associated with more advanced TNM stage (p = 0.002) (Supplemental Table 1). Importantly, high CENPF protein expression was correlated with poorer DFS and OS when compared to the low-expression group (HR 6.242, 95% CI 3.790 to 10.281, Log-rank p < 0.0001; HR 2.347, 95% CI 1.372 to 4.016, Log-rank p = 0.001, respectively) (Fig. 1G). Furthermore, multivariate Cox regression analysis demonstrated that high CENPF protein expression was an independent predictor for both DFS and OS in CRC patients (HR 5.282, 95% CI 3.162 to 8.822, p < 0.001; HR 2.074, 95% CI 1.192 to 3.607, p = 0.01, respectively) (Table 1). To ensure the reliability and applicability of these results, we conducted analogous examinations within an independent external validation cohort. Consistently, high CENPF protein expression was linked to poorer DFS and OS compared to the low-expression group in Cohort II (HR 3.309, 95% CI 1.393 to 7.862, Log-rank p = 0.004; HR 2.142, 95% CI 1.034 to 4.439, Log-rank p = 0.036, respectively) (Fig. 1H). Further validation through multivariate Cox regression analyses consistently demonstrated that elevated CENPF protein expression remained a strong and independent prognostic factor for both DFS and OS among CRC patients within the external validation cohort II (Table 2).

Table 1

Cox regression analysis of CENPF protein expression and clinicopathological covariates with survivals in the Cohort I
	Disease-free Survival				Overall Survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95%CI)	p Value	HR (95%CI)	p Value	HR (95%CI)	p Value	HR (95%CI)	p Value
CENPF-high vs. CENPF-low	6.242 (3.790-10.281)	<0.001	5.282 (3.162–8.822)	< 0.001	2.347 (1.372–4.016)	0.002	2.074 (1.192–3.607)	0.010
Age (≥ 60 vs. <60)	1.617 (0.959–2.724)	0.071			1.125 (0.647–1.955)	0.676
Sex (male vs. female)	0.933 (0.570–1.528)	0.783			0.797 (0.463–1.371)	0.412
Location (rectum vs colon)	1.292 (0.806–2.071)	0.288			0.714 (0.411–1.241)	0.233
TNM stage (III + IV vs I + II)	4.731 (2.829–7.911)	< 0.001	3.192 (1.818–5.605)	< 0.001	3.483 (1.992–6.091)	< 0.001	2.050 (1.097–3.832)	0.025
Differentiation grade (poorly vs others)	2.102 (1.213–3.640)	0.008	1.260 (0.678–2.344)	0.465	2.325 (1.282–4.218)	0.005	1.094 (0.555–2.156)	0.795
Adjuvant chemotherapy (yes vs no)	1.912 (1.104–3.310)	0.021	1.130 (0.635–2.012)	0.678	0.698 (0.409–1.192)	0.188
Lymphovascular invasion (yes vs no)	1.887 (1.031–3.456)	0.040	0.793 (0.406–1.547)	0.496	2.779 (1.512–5.109)	0.001	1.446 (0.732–2.860)	0.289
Perineural invasion (yes vs no)	2.461 (1.319–4.592)	0.005	1.770 (0.866–3.618)	0.118	2.514 (1.264–4.998)	0.009	1.942 (0.864–4.366)	0.108
Tumor size (cm) (≥ 4 vs < 4)	1.319 (0.819–2.124)	0.254			2.172 (1.262–3.738)	0.005	2.046 (1.156–3.621)	0.014
Serum CEA (ng/ml) (≥ 5 vs < 5)	1.651 (1.029–2.649)	0.038	1.158 (0.683–1.965)	0.586	2.206 (1.290–3.774)	0.004	1.317 (0.725–2.392)	0.366
Serum CA199 (U/ml) (≥ 37 vs < 37)	2.024 (1.118–3.663)	0.020	1.553 (0.808–2.988)	0.187	3.382 (1.884–6.069)	< 0.001	2.141 (1.118–4.099)	0.022
HR, hazard ratio; CI, confidence interval.

Table 2

Cox regression analysis of CENPF protein expression and clinicopathological covariates with survivals in the Cohort II
	Disease-free Survival				Overall Survival
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95%CI)	p Value	HR (95%CI)	p Value	HR (95%CI)	p Value	HR (95%CI)	p Value
CENPF-high vs. CENPF-low	3.309 (1.393–7.862)	0.007	3.991 (1.635–9.738)	0.002	2.142 (1.034–4.439)	0.040	2.651 (1.225–5.738)	0.013
Age (≥ 60 vs. <60)	1.699 (0.659–4.383)	0.273			1.886 (0.835–4.262)	0.127
Sex (male vs. female)	0.817 (0.339–1.973)	0.654			1.980 (0.806–4.865)	0.136
Location (rectum vs colon)	1.043 (0.574–1.894)	0.890			1.496 (0.913–2.452)	0.110
TNM stage (III + IV vs I + II)	2.021 (1.135–3.596)	0.017	2.544 (1.360–4.758)	0.003	3.566 (2.141–5.940)	< 0.001	3.751 (2.131-6.600)	< 0.001
Differentiation grade (poorly vs others)	1.502 (0.714–3.163)	0.284			1.619 (0.865–3.032)	0.132
Adjuvant chemotherapy (yes vs no)	2.101 (0.770–5.735)	0.147			1.347 (0.613–2.959)	0.458
Tumor size (cm) (≥ 4 vs < 4)	0.436 (0.183–1.039)	0.061			0.483 (0.231–1.013)	0.054	0.907 (0.395–2.081)	0.817
Serum CEA (ng/ml) (≥ 5 vs < 5)	2.492 (1.032–6.018)	0.042	1.696 (0.650–4.430)	0.280	1.868 (0.897–3.889)	0.095	1.740 (0.831–3.642)	0.142
Serum CA199 (U/ml) (≥ 37 vs < 37)	3.268 (1.352–7.895)	0.009	3.239 (1.197–8.763)	0.021	1.706 (0.727-4.000)	0.219
HR, hazard ratio; CI, confidence interval.

Taken together, these results strongly indicate that upregulated CENPF expression is tightly linked to an adverse prognosis in CRC and may play a role in CRC progression.

Knockdown of CENPF inhibits migration, invasion of colorectal cancer cells in vitro and in vivo

The prevalence of CENPF upregulation raises an intriguing possibility that CENPF overexpression may be a cancer-promoting event in CRC. To examined this possibility, CENPF expression was stably knock down using lentiviral vectors carrying two shRNAs targeting CENPF (shCENPF1 and shCENPF2) in DLD-1, HCT116, and SW480 cells. The knockdown efficiency was confirmed by Western blot assays (Supplemental Fig. 2A). Colorectal cancer cell migration and invasion ability was assessed in vitro. The migration and invasion assays showed that knocking down CENPF significantly weakened the ability of colorectal cancer cell migration and invasion (Fig. 2A). Similarly, scratch-wound-healing assays revealed that a lower migration ability in shCENPF cells than in shCtrl cells (Fig. 2B). To further exclude off-target effects of CENPF shRNA in CRC, CENPF-HA overexpression plasmids was transiently transfected into stably CENPF-knockdown DLD1, HCT116, and SW480 cells, examined by Western blot assays (Supplemental Fig. 3A). The migration and invasion assays revealed that CENPF overexpression significantly reversed the reduced migration and invasion compared to the vector group (Supplemental Fig. 3B). Moreover, scratch wound healing assays demonstrated a noticeable restoration of migration capacity in CENPF-overexpressing DLD1 and SW480 cells compared to vectors (Supplemental Fig. 3C). However, CCK-8 assays and Colony assays were used to investigate the role of CENPF in cell proliferation. The results revealed that knockdown of CENPF had no significant effect on CRC cell growth in vitro (Supplemental Fig. 4, A and B). Overall, these findings showed that CENPF can enhance the migration, and invasion of colorectal cancer cells in vitro.

We further examine whether the same result can be observed in vivo. CRC cells with or without CENPF knockdown were injected into spleen of the nude BALB/C mice (Supplemental Fig. 2B). Eight weeks post-injection, the ability of SW480 and DLD1 cells to develop liver micrometastases were significantly impaired when cells lacked CENPF (Fig. 2, C-D). Similarly, histological examination showed that the shCENPF group developed less liver micrometastases (Supplemental Fig. 2, C-D). Consistently, CENPF knockdown prolonged mouse survival (Fig. 2E). However,

no significant difference in tumor size was observed between CENPF knock-down group and shCtrl group (Supplemental Fig. 4C). Together, these results indicated that CENPF functioned as a tumor promoter in CRC metastasis.

Identification of USP4 as a candidate DUB for CENPF

Previous studies have revealed that several members of the CENP family, such as CENPA[32], CENPH[33], and CENPN[34], are degraded through the ubiquitin-proteasome pathway. Given this, we further investigated whether the CENPF protein follows a similar degradation pathway. Initially, we utilized protein modification site prediction tools and identified several potential ubiquitination sites on the CENPF protein structure. (Supplemental Fig. 5A). Western blotting showed CENPF protein increased with MG132 treatment, proteasome inhibitor, in a dose-dependent manner (Fig. 3A). And we performed co-immunoprecipitation (Co-IP) assays by transfecting HCT116 cells with CENPF-HA and Flag-Ubiquitin, and anti-HA immunoprecipitates were probed for the level of ubiquitination using Flag-antibody (Fig. 3B). It was discovered that CENPF undergoes ubiquitination, suggesting its degradation in CRC via the ubiquitination-proteasome pathway.

The proteasome identifies proteins tagged with ubiquitin and breaks them down into smaller peptides and amino acids. Conversely, deubiquitinating enzymes (DUBs) work to remove or cleave ubiquitin molecules from protein substrates, playing a crucial role in numerous cellular processes as a key regulatory mechanism [35]. To identify potential DUBs for CENPF, we screened DUBs expression library consisting of 53 human DUBs in HEK293T cells. HA-tagged CENPF was co-transfected with 53 DUBs-Flag plasmids separately into HEK293T cells, and expression of CENPF was detected using WB 72h after transfection. After the initial round of screening (Supplemental Fig. 5B), eighteen candidate DUBs that stabilized CENPF level significantly, were tested in the second round of screening in HCT116 CRC cells (Fig. 3C). Among the candidates, USP4 could interact with CENP. Immunoprecipitation with anti-Myc antibody demonstrated that Myc-USP4 interacted with overexpressed CENPF-HA (Fig. 3D). We then identified which USP4 regions are critically required for its interaction with CENPF. We generated four USP4 truncations (Fig. 3E), and through Co-IP assays, we found that the USP domain mediated association with CENPF (Fig. 3F). Therefore, USP4 could interact with CENPF and markedly stabilized CENPF protein expression levels, which was the most promising candidate based on the overlap of these two screenings.

USP4 deubiquitinates and stabilizes CENPF

To further elucidate the role of USP4 in its interaction with CENPF, further investigations demonstrated that USP4 could stabilize endogenously and exogenously expressed CENPF (Fig. 4, A-B). USP4 knockdown significantly reduced CENPF protein expression (Fig. 4C). However, neither the overexpression (Supplemental Fig. 6A) nor the knockdown (Supplemental Fig. 6B) of USP4 affected CENPF mRNA levels, indicating that USP4 stabilized CENPF protein levels post-transcriptionally.

USP4 is categorized as a cysteine protease, with bioinformatic analyses pinpointing C311 as the crucial catalytic cysteine. Consequently, USP4 mutant variant was created, wherein a substitution of cysteine to serine at position 311 (C311S) was introduced, rendering the enzyme catalytically deficient. To whether USP4 can indeed deubiquitinate CENPF, HCT116 cells were transfected with CENPF-HA, Flag-UB, USP4-Myc or USP4 C311S-Myc, and then anti-HA immunoprecipitates were probed for the level of ubiquitination using Flag-antibody Co-expression of USP4 and CENPF led to a notable effect on diminishing ubiquitination of CENPF (Fig. 4D). However, enzyme-inactive mutant USP4 C311S was not able to reduce CENPF ubiquitination (Fig. 4D). Moreover, overexpression of WT USP4, but not the enzyme-inactive mutant USP4 C311S, could stabilize CENPF protein (Fig. 4E). These results suggested that deubiquitylation and stabilization of CENPF was dependent on the catalytic activity of USP4. We next tested whether USP4 indeed extended CENPF’s protein half-life by cycloheximide chase assay. Similarly, overexpression of WT USP4, but not USP4 C311S, prolonged the half-life of CENPF (Fig. 4F). Conversely, When USP4 was depleted from HCT116 cells, the half-life of CENPF was markedly reduced (Fig. 4F). These data demonstrated that USP4 interacts with CENPF and facilitates ubiquitination of CENPF, stabilizing it and prolonging its lifespan when overexpressed. Conversely, depletion of USP4 reduces CENPF's lifespan.

To confirm the relevance of the USP4-CENPF interaction, we first analyzed protein expression of USP4 and CENPF in our clinical samples from two different Cohort. We found that USP4 and CENPF expression were positively correlated (Fig. 4G). Representative immunostaining results were presented in Fig. 4H. However, public dataset analysis of USP4 and CENPF mRNA levels did not mirror these results (Supplemental Fig. 6C). Notably, a high expression level of USP4 correlated with poor prognosis of CRC patients from two different cohorts (Supplemental Fig. 7A). Taken together, these findings suggested that USP4 was a strong DUB for CENPF, which at least partially, contributed to the upregulated CENPF protein expression.

CENPF is positively regulated by USP4 and affects the metastatic ability of CRC cells

After identifying the interaction between USP4 and CENPF, we further examined the effectiveness of USP4 on the CENPF mediated enhanced CRC migration, invasion, and metastasis capacity. In HCT116 and DLD1 cell lines, we knocked down CENPF using shCENPF and stably overexpressed USP4 for subsequent research. Western blot analysis was utilized to detect the levels of USP4 and CENPF in cell lines from various groups, as illustrated in Fig. 5A. The transwell assays and wound healing assays were employed to assess the invasion and migration capabilities. The results showed that overexpressing USP4 significantly enhanced CRC^’s migratory ability under CENPF-knocking down conditions (Fig. 5, B-C). Additionally, we investigated whether similar results could be observed in vivo. These findings were reinforced by conducting an animal study, where DLD1 cells were injected into the spleen of nude mice using established methods. Compared to the shCtrl, tumor lesions in the shCENPF group were scarcely visible in the liver (Fig. 5D). However, upregulating USP4 expression could greatly enhance the the ability of CENPF-knockdown CRC cell to form liver micrometastases (Fig. 5D). The same result was also observed in HE stains result (Fig. 5E). Thus, we proved that CENPF can positively be regulated by USP4 and affects the metastatic ability of CRC cells in vitro and in vivo.

The USP4-CENPF axis was correlated with clinical outcomes of CRC patients

Expanding on previous discoveries linking CENPF and USP4 to CRC patient prognosis and their involvement in CRC metastasis regulation, we explored the prognostic relevance of USP4-CENPF association. We categorized samples from cohort I into four groups according to their USP4 and CENPF protein levels determined by IHC analysis. These categories comprised low USP4/low CENPF, low USP4/high CENPF, high USP4/low CENPF, and high USP4/high CENPF. Subsequently, we conducted comparisons of clinical outcomes among these groups. Kaplan–Meier analysis suggested that patients with

high USP4 and high CENPF expression tended to have the poorest DFS and OS compared with the other groups (Fig. 6A). These data imply that the USP4–CENPF axis plays a role in CRC development.

Tumor recurrence is identified as a significant adverse prognostic indicator in patients with colorectal cancer (CRC) following curative resection [2]. In our study, we're looking into new key genes for CRC using bioinformatics, especially those linked to autophagy-related genes. We firstly identified CENPF as a top candidate gene in CRC progression, examined its functional role in metastatic progression and demonstrated the therapeutic value of targeting CENPF in inhibiting CRC liver metastasis. Mechanically, we found CENPF protein could undergo ubiquitination, leading to subsequent proteasomal degradation. And USP4 as a deubiquitinating enzyme (DUB), interacted with and deubiquitinated CENPF, thereby stabilizing it. Taken together, our data showed that a novel USP4-CENPF axis played an important regulatory role in CRC metastasis and may serve as a potential target for CRC treatment.

Due to the complexity and variability of CRC, effective targeted therapies for CRC and the availability of effective signatures that can accurately predict recurrence remain limited [20]. Autophagy, as a mechanism supporting cell survival, has emerged as a pivotal factor in cancer metastasis. Its impact can be twofold: either promoting or inhibiting metastasis, contingent upon factors such as cancer cell subtype, the tumor microenvironment, and the stage of tumor progression [36, 37]. We conducted correlation analysis using multiple transcriptome sequencing datasets in CRC and an autophagy gene list to identify candidate gene sets. We then intersected the differences between cancer and adjacent tissues to identify potential important targets for CRC treatment, in which is a candidate set comprising 54 genes. Among them, fifteen candidate genes, including DACH1, GALNT6, IFITM1, EGFL6, WNT5A, CDK1, GDF15, SOX9, KIF23, CPNE1, BHLHE40, NEK2, ASPM, PLA2G16, and PMEPA1, have been proven to play important roles in CRC [38–52], which indicated a certain degree of reliability in our screening process. Using two different siRNAs to target candidate genes, we examined their effects on the migratory capacity of HCT116 colorectal cancer cells. Interestingly, knocking down CENPF with siRNA showed the most pronounced inhibition of HCT116 migration, which has not been previously reported. Therefore, the role of CENPF in CRC has become the focus of our research. Moreover, leveraging data from GEO, TCGA databases, and our own colorectal cancer tissue microarrays from two different centers, we explored CENPF expression patterns and prognostic significance in CRC. Consistently, findings indicated upregulation of both CENPF mRNA and protein in colorectal tumors compared to adjacent normal tissues. In addition, CENPF expression correlated with CRC prognosis, showing more significant predictive efficacy in disease-free survival, indicating its potential oncogenic role in CRC metastasis. Previous results have demonstrated that CENPF was highly expressed in the lung adenocarcinoma (LUAD), and CENPF expression correlated with T stage and poor prognosis [53]. Moreover, CENPF knockout significantly inhibited LUAD cell growth, the tumor growth of mice [53]. Also, CENPF is markedly elevated in pancreatic cancer (PC) and linked to poor patient outcomes [5]. Knocking down CENPF inhibits PC cell proliferation, migration, and EMT, inducing G2/M phase cell cycle arrest and restraining in vivo pancreatic cell growth [5]. Importantly, knocking down CENPF expression significantly altered invasive and migratory capacity of CRC cells, as evidenced from a series of in vitro experiments and in xenograft nude mice models of

liver metastasis in vivo. Therefore, the consistent results from our comprehensive study verified CENPF acted as a novel tumor oncogene in CRC.

Another major finding of our study is that we've uncovered the role of ubiquitination in controlling CENPF protein expression and its functions. Until now, there have been few reports confirming the factors that regulate CENPF expression. Previous research has shown that several members of the CENP family, including CENPA, CENPH, and CENPN, are degraded via the ubiquitin-proteasome pathway[32–34]. First, we discovered that MG132 effectively blocked the degradation of CENPF protein and CENPF underwent ubiquitination modifications, suggesting that CENPF could be regulated by ubiquitin-proteasome axis. To further identify the DUBs that can potentially deubiquitinate

and stabilize CENPF, we screened a human DUB expression library consisting of 53 DUBs-Flag plasmids in HEK293T cells. The top 18 knockdowns of DUB genes that stabilized CENPF level most significantly were selected for a second-round screening

genes. Each of those DUBs was then co-overexpressed together with HA-CENPF in HCT116 cells. Coimmunoprecipitation (co-IP) experiments showed the interaction exists exclusively between USP4 and CENPF. Based on two rounds of screening, we propose that USP4 is the most likely deubiquitinase regulating CENPF stability. Mechanically, USP4 interacts with CENPF and decreases CENPF ubiquitination levels, thus stabilizing it. Accordingly, USP4 expression was significantly positively corelated with CENPF in human CRC samples from two different tertiary hospitals in China, as confirmed by immunohistochemistry. Importantly, the interaction of CENPF and USP4 then controlled the invasion and migration of colorectal cancer. Previous evidence has confirmed a critical role for USP4 in regulating p53, TGFβ, Wnt/β-catenin, and NF-κB signaling, implicating dysregulation of USP4 expression in the development of cancer [54]. In CRC, USP4 has been shown to promote colorectal cancer cell metastasis in vitro and in vivo by regulating the stability and activity of β-catenin and PRL-3 [20, 22]. Previous studies showed that mutating the catalytic residue Cys311 to Ala abolishes USP4's deubiquitination and stabilization of β-catenin. In our study, the C311S mutation in USP4 also lost its ability to stabilize and deubiquitinate CENPF. Thus, we speculate that CENPF is a key downstream target of USP4 in regulating colorectal cancer metastasis. Furthermore, high USP4 and high CENPF are significant determinants of poor survival in patients with CRC.

This study had some limitations as follows. First, we explained how post-translational modifications regulate CENPF's abnormal expression and function. However, we also found that CENPF transcription levels are abnormally elevated in colorectal cancer. Understanding the mechanisms behind this upregulation is essential for effectively targeting CENPF abnormalities. Second, the role of the CENPF-USP4 axis in CRC metastasis has been identified, but the specific downstream molecular mechanisms remain unclear and require further investigation.

In summary, our groundbreaking research, for the first time, has unveiled CENPF as a novel promoter of CRC metastasis and elucidate the molecular mechanism of the interaction between CENPF and USP4 in inducing migration and invasion of colorectal cancer cells, evidenced from molecular, cellular, animal models, and clinical specimens. Thus, USP4-CENPF axis may represent a potential therapeutic target and predictive markers in CRC.

Ethics statement

Ethical approval

was obtained from the institutional review boards at each participating center (KY2021-R019, 2023KY251) for the retrospective analysis of anonymized data. All procedures involving animals were conducted in accordance with institutional ethical standards for animal experimentation and were approved by the Ethics Committee of Fujian Medical University/Laboratory Animal Center (IACUC FJMU 2022 − 0488).

Study patients

The study enrolled a total of 519 patients diagnosed with typical colorectal adenocarcinoma histology. Formalin-fixed, paraffin-embedded (FFPE) specimens were collected from 393 patients who underwent curative surgery at the First Affiliated Hospital, Wenzhou Medical University (Wenzhou, China) from April 2014 to December 2016, constituting Cohort I for the training dataset. Additionally, 126 patients who underwent curative surgery at Union Hospital, Fujian Medical University (Fuzhou, China) from January 2010 to December 2012 formed Cohort II for external validation. Detailed information on the inclusion and exclusion criteria, along with details of the recruitment process, can be found in Supplemental Fig. 9. The baseline characteristics of these patients are summarized in Supplemental Table 1.

Follow-up and Survival analysis

Patients included in the study underwent follow-up examinations every 3 months during the initial 2 years post-surgery, followed by 6-month intervals for the subsequent 3 years. The last recorded follow-up data were available until September 6, 2021, for patients from Cohort I and until September 1, 2018, for patients from Cohort II. Survival analysis was conducted on patients with complete immunohistochemistry (IHC) data. To determine the optimal cutoff point for epithelial CENPF IHC scores, X-tile software was utilized to establish this cutoff, which correlates CENPF protein expression with DFS. The same threshold values (CENPF IHC score = 170) were then applied to the independent external validation cohorts. Survival analyses were conducted to evaluate the potential relationship between CENPF protein expression and OS and DFS. Additionally, the optimal cutoff values (IHC score = 100) for USP4 were also determined using X-tile software, followed by subsequent survival analysis.

Immunohistochemistry

Immunohistochemistry (IHC) was performed at the Pathology Laboratory of Union Hospital using rabbit polyclonal antibodies to USP4 (1:1000, ab236987, Abcam) and rabbit polyclonal antibodies to CENPF (1:500, ab5, Abcam), following the manufacturer's instructions. IHC scores were independently assessed by two pathologists blinded to clinicopathological data, utilizing a scoring system described previously [55]. The reliability of the scoring system was evaluated by analyzing the agreement between the scoring results obtained by the two independent investigators using contingency tables (Supplemental Table 2–3). Cohen’s Kappa Indices were calculated to measure inter-rater agreement, with a result considered to indicate excellent concordance if the Cohen’s Kappa index exceeded 0.8 [56].

Genomic data mining

Data from GSE14333, GSE41258, and TCGA datasets were obtained from the Gene Expression Ominous (GEO) and TCGA. Then, we extracted corresponding autophagy genes (Supplemental Table 4) expression profile and protein-coding genes from 3 dataset, respectively. In the R 3.2.0 environment, we iteratively explored the correlation between them to identify a candidate set of autophagy-related genes.

In the R 3.2.0 environment, we employed the plyr, reshape2, and ggpubr packages to process the raw data from TCGA dataset and display the expression pattern of CENPF mRNA across various cancers.

The limma package was employed to explore differentially expressed genes between colorectal cancer (CRC) and adjacent normal tissues in GSE41258 and GSE49355. Additionally, two datasets (GSE8671, GSE22598) were used to investigate the differential expression of CENPF mRNA between colorectal cancer and adjacent normal tissues.

Survival data including disease-free survival (DFS) were annotated from the GSE14333 dataset. The prognostic relevance of CENPF mRNA expression level was investigated in GSE14333 cohort. The X-tile plot curve was utilized to present the relationship between CENPF mRNA expression and DFS, determining the optimal cut-off value to stratify patients. Patients with CENPF mRNA expression above the cut-off value were categorized into the CENPF-high group, while those below were categorized into the CENPF-low group. The Kaplan-Meier method was employed to examine the relationship between different patient groups and DFS.

Cell models

Cell lines including HCT116, SW480, DLD1 (human colorectal cancer cell lines), and HEK293T (human embryonic kidney epithelial cell line) were obtained from Punuo Sai Life Sciences & Technology Co., Ltd. in Wuhan, China. Authentication of these cell lines was performed via STR profiling. Culture conditions were as follows: HCT116 and DLD1 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (Sigma, Missouri, USA) and penicillin/streptomycin, maintained in a 5% CO2 humidified incubator. SW480 and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine serum and penicillin/streptomycin, also within a 5% CO2 humidified incubator. All cell lines used in this study were confirmed to be free of mycoplasma contamination.

Immunoprecipitation and ubiquitination assays

In both experiments, cell lysis was performed using a homemade lysis buffer kept on ice. The lysis buffer contained 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 2.5 mM Sodium pyrophosphate, 1 mM β-Glycerophosphate, and 1 mM Na3VO4, supplemented with a protease inhibitor cocktail.

After centrifugation at 12,000×g for 30 minutes at 4°C, 5% of the supernatant lysates were retained as input for future use. For the immunoprecipitation of endogenous proteins, protein A/G agarose (obtained from Santa Cruz Biotechnology, Santa Cruz, USA) was washed thrice with lysis buffer and then incubated with the specified antibody along with the remaining cell lysate supernatant at 4°C overnight. In the case of immunoprecipitation for exogenously overexpressed proteins, anti-Flag (GNI4510-FG), HA (GNI4510-HA), or Myc (GNI4510-MC) affinity gel (obtained from GNI, Tokyo, Japan) was washed three times with lysis buffer and directly incubated with the remaining cell lysate supernatant at 4°C overnight. Subsequent Western blot analysis was conducted the following day after washing three times with lysis buffer.

Transwell migration assay

Tumor cell migration assays were conducted following the manufacturer's guidelines. Initially, cells were harvested and suspended in serum-free medium. Subsequently, they were seeded onto Transwell inserts at a concentration of 200,000 cells per well. These inserts were then positioned in a lower chamber containing 600 µl of culture media supplemented with 20% FBS. The Transwells were then incubated for 24 hours at 37°C.

Following incubation, cells on the interior of the Transwell inserts were eliminated using a cotton swab. The cells that had migrated to the lower surface of the membrane were then fixed using 4% paraformaldehyde and stained with 0.1% crystal violet. Photographs were captured from five randomly selected fields, and the cells were counted to determine the average number of cells that had migrated.

Tumor growth and liver metastasis assay in nude mice

Five-week-old female athymic nude mice were obtained from the GemPharmatech Co., Ltd (Nanjing, China). The mice were subcutaneously injected with either 3 × 10⁶ DLD-1 cells or SW480 cells or HCT116 cells transduced with lenti-shCtrl or lenti-shCENPF1 or lenti-shCENPF2. Tumor volume (mm³) was calculated using the formula: Volume = 0.5 × length × (width)².

To assess the metastatic potential of colorectal cancer (CRC) cells in the liver, athymic nude mice (n = 6 per group) were utilized, following established protocols. Briefly, a small incision was made in the left abdomen, and the spleen was isolated and exposed. Viable cancer cells (3 × 10⁶ cells/50 µl PBS) were injected into the spleen using a sterile tuberculin syringe and a 27-gauge needle. Then, the abdominal cavity was closed using nylon sutures. Mice were euthanized after eight weeks (for DLD-1 and SW480 cells), and liver metastases were subsequently evaluated.

CCK-8 assay, colony formation assy

The viability of cells was assessed using the Cell Counting Kit-8 (CCK-8) from Dojindo Molecular Technologies, Inc. Cells were seeded into triplicate wells of 96-well plates at a density of 2,000 cells per well for the CCK-8 assay. For the colony formation assay, cells were cultured in triplicate wells of 6-well plates at a density of 500 cells per well. Following a two-week incubation period under standard growth conditions, the colonies were fixed with ice-cold 4% paraformaldehyde, stained with crystal violet solution, and examined using an inverted microscope.

Statistical Analysis

Statistical analyses were performed using R (version 3.5.0) and SPSS (version 16.0.2). Significance was set at p < 0.05 for all two-tailed tests. Experiments included 3 to 8 samples per group, with results reported as mean ± SE from at least 3 independent experiments. The Shapiro-Wilk test assessed data normality. For normally distributed data, independent sample t-tests compared two groups, and one-way ANOVA compared three or more groups. Pearson's correlation tested relationships between variables. For non-normally distributed data, the Mann-Whitney test compared two groups, Kruskal-Wallis test compared three or more groups, and Spearman's rank correlation tested relationships. Two-way ANOVA analyzed repeated measurements. Clinical characteristic comparisons used Mann-Whitney U, Fisher’s exact, or chi-square tests. X-tile software optimized cutoff values for marker expression subgroups. Kaplan-Meier analysis and log-rank tests estimated overall and disease-free survival, while multivariate Cox regression assessed marker contributions to survival outcomes.

COMPETING INTERESTS

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

AUTHOR CONTRIBUTIONS

Z. Xie: writing–original draft, project administration, formal analysis, investigation and validation. H. Lin, Y. Wu, X. Wang, Y. Yu, J, Wu, M. Xu, Y. Han, Q. Zhang, Y. Deng, L. Lin, L. Yan, Q. Li: Investigation and validation. X. Lin: writing–original draft, supervision, project administration, writing–review and editing. Y, Huang: writing–original draft, supervision, project administration, P. Chi: Supervision, funding acquisition, project administration, writing–review and editing.

ACKNOWLEDGEMENTS

This work was supported by the Construction Project of Fujian Province Minimally Invasive Medical Center ([2017]171), Joint Funds for innovation of Science and Technology, Fujian province (2020Y9071), Fujian provincial health technology project (2020CXA025).

F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68 (2018) 394–424.
G.A. Pihan, J. Wallace, Y. Zhou, S.J. Doxsey, Centrosome abnormalities and chromosome instability occur together in pre-invasive carcinomas, Cancer Res, 63 (2003) 1398–1404.
E.B. Chen, X. Qin, K. Peng, Q. Li, C. Tang, Y.C. Wei, S. Yu, L. Gan, T.S. Liu, HnRNPR-CCNB1/CENPF axis contributes to gastric cancer proliferation and metastasis, Aging (Albany NY), 11 (2019) 7473–7491.
M. Li, J. Zhao, R. Yang, R. Cai, X. Liu, J. Xie, B. Shu, S. Qi, CENPF as an independent prognostic and metastasis biomarker corresponding to CD4 + memory T cells in cutaneous melanoma, Cancer Sci, 113 (2022) 1220–1234.
H. Chen, X. Wang, F. Wu, X. Mo, C. Hu, M. Wang, H. Xu, C. Yao, H. Xia, L. Lan, Centromere protein F is identified as a novel therapeutic target by genomics profile and contributing to the progression of pancreatic cancer, Genomics, 113 (2021) 1087–1095.
A. Aytes, A. Mitrofanova, C. Lefebvre, M.J. Alvarez, M. Castillo-Martin, T. Zheng, J.A. Eastham, A. Gopalan, K.J. Pienta, M.M. Shen, A. Califano, C. Abate-Shen, Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy, Cancer Cell, 25 (2014) 638–651.
S.L. O'Brien, A. Fagan, E.J. Fox, R.C. Millikan, A.C. Culhane, D.J. Brennan, A.H. McCann, S. Hegarty, S. Moyna, M.J. Duffy, D.G. Higgins, K. Jirström, G. Landberg, W.M. Gallagher, CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer, Int J Cancer, 120 (2007) 1434–1443.
K.D. Wilkinson, Protein ubiquitination: a regulatory post-translational modification, Anticancer Drug Des, 2 (1987) 211–229.
T. Cardozo, M. Pagano, The SCF ubiquitin ligase: insights into a molecular machine, Nat Rev Mol Cell Biol, 5 (2004) 739–751.
D. Popovic, D. Vucic, I. Dikic, Ubiquitination in disease pathogenesis and treatment, Nat Med, 20 (2014) 1242–1253.
F.E. Reyes-Turcu, K.H. Ventii, K.D. Wilkinson, Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes, Annu Rev Biochem, 78 (2009) 363–397.
M.E. Sowa, E.J. Bennett, S.P. Gygi, J.W. Harper, Defining the human deubiquitinating enzyme interaction landscape, Cell, 138 (2009) 389–403.
A. Mofers, P. Pellegrini, S. Linder, P. D'Arcy, Proteasome-associated deubiquitinases and cancer, Cancer Metastasis Rev, 36 (2017) 635–653.
M.J. Clague, S. Urbé, D. Komander, Breaking the chains: deubiquitylating enzyme specificity begets function, Nat Rev Mol Cell Biol, 20 (2019) 338–352.
T. Li, B. Yan, Y. Ma, J. Weng, S. Yang, N. Zhao, X. Wang, X. Sun, Ubiquitin-specific protease 4 promotes hepatocellular carcinoma progression via cyclophilin A stabilization and deubiquitination, Cell Death Dis, 9 (2018) 148.
H. Zhang, Y. Han, W. Xiao, Y. Gao, Z. Sui, P. Ren, F. Meng, P. Tang, Z. Yu, USP4 promotes the proliferation, migration, and invasion of esophageal squamous cell carcinoma by targeting TAK1, Cell Death Dis, 14 (2023) 730.
X. Zhang, F.G. Berger, J. Yang, X. Lu, USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1, Embo j, 30 (2011) 2177–2189.
B. Zhao, C. Schlesiger, M.G. Masucci, K. Lindsten, The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway, J Cell Mol Med, 13 (2009) 1886–1895.
Z. Li, Q. Hao, J. Luo, J. Xiong, S. Zhang, T. Wang, L. Bai, W. Wang, M. Chen, W. Wang, L. Gu, K. Lv, J. Chen, USP4 inhibits p53 and NF-κB through deubiquitinating and stabilizing HDAC2, Oncogene, 35 (2016) 2902–2912.
S.I. Yun, H.H. Kim, J.H. Yoon, W.S. Park, M.J. Hahn, H.C. Kim, C.H. Chung, K.K. Kim, Ubiquitin specific protease 4 positively regulates the WNT/β-catenin signaling in colorectal cancer, Mol Oncol, 9 (2015) 1834–1851.
L. Zhang, F. Zhou, Y. Drabsch, R. Gao, B.E. Snaar-Jagalska, C. Mickanin, H. Huang, K.A. Sheppard, J.A. Porter, C.X. Lu, P. ten Dijke, USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-β type I receptor, Nat Cell Biol, 14 (2012) 717–726.
C. Xing, X.X. Lu, P.D. Guo, T. Shen, S. Zhang, X.S. He, W.J. Gan, X.M. Li, J.R. Wang, Y.Y. Zhao, H. Wu, J.M. Li, Ubiquitin-Specific Protease 4-Mediated Deubiquitination and Stabilization of PRL-3 Is Required for Potentiating Colorectal Oncogenesis, Cancer Res, 76 (2016) 83–95.
R. Mathew, V. Karantza-Wadsworth, E. White, Role of autophagy in cancer, Nat Rev Cancer, 7 (2007) 961–967.
M. Farhan, M. Silva, S. Li, F. Yan, J. Fang, T. Peng, J. Hu, M.S. Tsao, P. Little, W. Zheng, The role of FOXOs and autophagy in cancer and metastasis-Implications in therapeutic development, Med Res Rev, 40 (2020) 2089–2113.
M. Garg, Epithelial Plasticity, Autophagy and Metastasis: Potential Modifiers of the Crosstalk to Overcome Therapeutic Resistance, Stem Cell Rev Rep, 16 (2020) 503–510.
R. Gundamaraju, W. Lu, M.K. Paul, N.K. Jha, P.K. Gupta, S. Ojha, I. Chattopadhyay, P.V. Rao, S. Ghavami, Autophagy and EMT in cancer and metastasis: Who controls whom?, Biochim Biophys Acta Mol Basis Dis, 1868 (2022) 166431.
Y. Dong, Q. Jin, M. Sun, D. Qi, H. Qu, X. Wang, C. Quan, CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy, J Exp Clin Cancer Res, 42 (2023) 68.
T. Fan, X. Wang, S. Zhang, P. Deng, Y. Jiang, Y. Liang, S. Jie, Q. Wang, C. Li, G. Tian, Z. Zhang, Z. Ren, B. Li, Y. Chen, Z. He, Y. Luo, M. Chen, H. Wu, Z. Yu, H. Pi, Z. Zhou, Z. Zhang, NUPR1 promotes the proliferation and metastasis of oral squamous cell carcinoma cells by activating TFE3-dependent autophagy, Signal Transduct Target Ther, 7 (2022) 130.
J.H. Han, Y.K. Kim, H. Kim, J. Lee, M.J. Oh, S.B. Kim, M. Kim, K.H. Kim, H.J. Yoon, M.S. Lee, J.D. Minna, M.A. White, H.S. Kim, Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells, Cancer Commun (Lond), 42 (2022) 716–749.
T. Marsh, J. Debnath, Autophagy suppresses breast cancer metastasis by degrading NBR1, Autophagy, 16 (2020) 1164–1165.
Q. Zhu, Q. Zhang, M. Gu, K. Zhang, T. Xia, S. Zhang, W. Chen, H. Yin, H. Yao, Y. Fan, S. Pan, H. Xie, H. Liu, T. Cheng, P. Zhang, T. Zhang, B. You, Y. You, MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma, Autophagy, 17 (2021) 1667–1683.
K. Wang, Y. Liu, Z. Yu, B. Gu, J. Hu, L. Huang, X. Ge, L. Xu, M. Zhang, J. Zhao, M. Hu, R. Le, Q. Wu, S. Ye, S. Gao, X. Zhang, R.M. Xu, G. Li, Phosphorylation at Ser68 facilitates DCAF11-mediated ubiquitination and degradation of CENP-A during the cell cycle, Cell Rep, 37 (2021) 109987.
N. Miyajima, S. Maruyama, K. Nonomura, S. Hatakeyama, TRIM36 interacts with the kinetochore protein CENP-H and delays cell cycle progression, Biochem Biophys Res Commun, 381 (2009) 383–387.
B. Li, Z. Li, C. Lu, L. Chang, D. Zhao, G. Shen, T. Kusakabe, Q. Xia, P. Zhao, Heat Shock Cognate 70 Functions as A Chaperone for the Stability of Kinetochore Protein CENP-N in Holocentric Insect Silkworms, Int J Mol Sci, 20 (2019).
D. Mennerich, K. Kubaichuk, T. Kietzmann, DUBs, Hypoxia, and Cancer, Trends Cancer, 5 (2019) 632–653.
I. Dikic, Z. Elazar, Mechanism and medical implications of mammalian autophagy, Nat Rev Mol Cell Biol, 19 (2018) 349–364.
C.M. Dower, C.A. Wills, S.M. Frisch, H.G. Wang, Mechanisms and context underlying the role of autophagy in cancer metastasis, Autophagy, 14 (2018) 1110–1128.
X. Hu, L. Zhang, Y. Li, X. Ma, W. Dai, X. Gao, X. Rao, G. Fu, R. Wang, M. Pan, Q. Guo, X. Xu, Y. Zhou, J. Gao, Z. Zhang, S. Cai, J. Peng, G. Hua, Organoid modelling identifies that DACH1 functions as a tumour promoter in colorectal cancer by modulating BMP signalling, EBioMedicine, 56 (2020) 102800.
J. Duan, L. Chen, H. Gao, T. Zhen, H. Li, J. Liang, F. Zhang, H. Shi, A. Han, GALNT6 suppresses progression of colorectal cancer, Am J Cancer Res, 8 (2018) 2419–2435.
F. Yu, D. Xie, S.S. Ng, C.T. Lum, M.Y. Cai, W.K. Cheung, H.F. Kung, G. Lin, X. Wang, M.C. Lin, IFITM1 promotes the metastasis of human colorectal cancer via CAV-1, Cancer Lett, 368 (2015) 135–143.
T.Y. Sung, H.L. Huang, C.C. Cheng, F.L. Chang, P.L. Wei, Y.W. Cheng, C.C. Huang, Y.C. Lee, W.C. HuangFu, S.L. Pan, EGFL6 promotes colorectal cancer cell growth and mobility and the anti-cancer property of anti-EGFL6 antibody, Cell Biosci, 11 (2021) 53.
M. Tufail, C. Wu, WNT5A: a double-edged sword in colorectal cancer progression, Mutat Res Rev Mutat Res, 792 (2023) 108465.
K. Zeng, W. Li, Y. Wang, Z. Zhang, L. Zhang, W. Zhang, Y. Xing, C. Zhou, Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer, Adv Sci (Weinh), 10 (2023) e2301088.
H. Lin, Y. Luo, T. Gong, H. Fang, H. Li, G. Ye, Y. Zhang, M. Zhong, GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer, Cell Oncol (Dordr), (2024).
X. Liang, G.N. Duronio, Y. Yang, P. Bala, P. Hebbar, S. Spisak, P. Sahgal, H. Singh, Y. Zhang, Y. Xie, P. Cejas, H.W. Long, A.J. Bass, N.S. Sethi, An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer, Gastroenterology, 162 (2022) 209–222.
Z. Ji, A. Mi, M. Li, Q. Li, C. Qin, Aberrant KIF23 expression is associated with adverse clinical outcome and promotes cellular malignant behavior through the Wnt/β-catenin signaling pathway in Colorectal Cancer, J Cancer, 12 (2021) 2030–2040.
Y. Wang, S. Pan, X. He, Y. Wang, H. Huang, J. Chen, Y. Zhang, Z. Zhang, X. Qin, CPNE1 Enhances Colorectal Cancer Cell Growth, Glycolysis, and Drug Resistance Through Regulating the AKT-GLUT1/HK2 Pathway, Onco Targets Ther, 14 (2021) 699–710.
E. Shan, Y. Huo, H. Wang, Z. Zhang, J. Hu, G. Wang, W. Liu, B. Yan, H. Hiroaki, J. Yang, Differentiated embryonic chondrocyte expressed gene-1 (DEC1) enhances the development of colorectal cancer with an involvement of the STAT3 signaling, Neoplasia, 27 (2022) 100783.
M.J. Ko, Y.R. Seo, D. Seo, S.Y. Park, J.H. Seo, E.H. Jeon, S.W. Kim, K.U. Park, D.B. Koo, S. Kim, J.H. Bae, D.K. Song, C.H. Cho, K.S. Kim, Y.H. Lee, RPL17 Promotes Colorectal Cancer Proliferation and Stemness through ERK and NEK2/β-catenin Signaling Pathways, J Cancer, 13 (2022) 2570–2583.
L. Wang, X.D. Hu, S.Y. Li, X.Y. Liang, L. Ren, S.X. Lv, ASPM facilitates colorectal cancer cells migration and invasion by enhancing β-catenin expression and nuclear translocation, Kaohsiung J Med Sci, 38 (2022) 129–138.
L. Yang, L. Zheng, X. Xie, J. Luo, J. Yu, L. Zhang, W. Meng, Y. Zhou, L. Chen, D. Ouyang, H. Zhou, Z. Tan, Targeting PLA2G16, a lipid metabolism gene, by Ginsenoside Compound K to suppress the malignant progression of colorectal cancer, J Adv Res, 36 (2022) 265–276.
L. Zhang, X. Wang, C. Lai, H. Zhang, M. Lai, PMEPA1 induces EMT via a non-canonical TGF-β signalling in colorectal cancer, J Cell Mol Med, 23 (2019) 3603–3615.
T. Hexiao, B. Yuquan, X. Lecai, W. Yanhong, S. Li, H. Weidong, X. Ming, Z. Xuefeng, P. Gaofeng, Z. Li, Z. Minglin, T. Zheng, Y. Zetian, Z. Xiao, C. Yi, M. Lanuti, Z. Jinping, Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway, Aging (Albany NY), 13 (2021) 2604–2625.
Y. Wang, L. Zhou, J. Lu, B. Jiang, C. Liu, J. Guo, USP4 function and multifaceted roles in cancer: a possible and potential therapeutic target, Cancer Cell Int, 20 (2020) 298.
W. Chang, X. Gao, Y. Han, Y. Du, Q. Liu, L. Wang, X. Tan, Q. Zhang, Y. Liu, Y. Zhu, Y. Yu, X. Fan, H. Zhang, W. Zhou, J. Wang, C. Fu, G. Cao, Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma, Gut, 63 (2014) 1457–1467.
X. Xu, L. Zhu, Y. Yang, Y. Pan, Z. Feng, Y. Li, W. Chang, J. Sui, F. Cao, Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts, British journal of cancer, 120 (2019) 987–995.

(Not answered)

Download PDF

Editorial decision: revise
22 Aug, 2024
Review #2 received at journal
12 Aug, 2024
Review #1 received at journal
09 Aug, 2024
Reviewer #2 agreed at journal
31 Jul, 2024
Reviewer #1 agreed at journal
28 Jul, 2024
Reviewers invited by journal
24 Jul, 2024
Submission checks completed at journal
04 Jul, 2024
First submitted to journal
03 Jul, 2024
Editor assigned by journal
03 Jul, 2024

You are reading this latest preprint version

USP4-mediated CENPF deubiquitylation regulated tumor metastasis in colorectal cancer

Status:

Version 1

Abstract

Figures

INTRODUCTION

RESULTS

Identification of CENPF as a Potential Participant in CRC Progression

Knockdown of CENPF inhibits migration, invasion of colorectal cancer cells in vitro and in vivo

Identification of USP4 as a candidate DUB for CENPF

USP4 deubiquitinates and stabilizes CENPF

CENPF is positively regulated by USP4 and affects the metastatic ability of CRC cells

The USP4-CENPF axis was correlated with clinical outcomes of CRC patients

DISCUSSION

MATERIALS AND METHODS

Ethics statement

Study patients

Follow-up and Survival analysis

Immunohistochemistry

Genomic data mining

Cell models

Immunoprecipitation and ubiquitination assays

Transwell migration assay

Tumor growth and liver metastasis assay in nude mice

CCK-8 assay, colony formation assy

Statistical Analysis

Declarations

COMPETING INTERESTS

AUTHOR CONTRIBUTIONS

ACKNOWLEDGEMENTS

References

Additional Declarations

Supplementary Files

Status:

Version 1